Video Library

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses optimal follow up for patients after resection of an early-stage non-small cell lung cancer (NSCLC).

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses if immunotherapy should stop in responding patients after a fixed duration of treatment.

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses the changing landscape of first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC).

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses the changing standard of care for stage 3 non-small cell lung cancer (NSCLC).

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of fms related tyrosine kinase 3 (flt3) and myeloproliferative neoplasms (MPN) mutations in acute myeloid leukemia (AML) (¿Cuál es el rol de la tirosina cinasa 3 afín a FMS (FLT3) y de las mutaciones en las neoplasias

GRACE sat down with Dr. Marco Ruiz to discuss information regarding when and who to refer for hematopoietic cell transplantation (HCT) (¿Cuándo y para quién se recomienda el trasplante de células hematopoyéticas (TCH)?). Stay tuned for more on our continuing video series with our Spanish speaking

GRACE sat down with Dr. Marco Ruiz to discuss information regarding acute myeloid leukemia (AML) in elderly patients (Leucemia aguda mieloide (LMA) en la población de tercera edad). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer

Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses Is There An Optimal Chemo Regimen For Squamous Non-Small Cell Lung Cancer (NSCLC).

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.